Lysosomal Storage Disorders: Azafaros Takes Aim At Small Molecules
BioGeneration Ventures has given birth to a new European biotech, Azafaros, supplying seed funding for the development of a new generation of compounds to tackle rare metabolic disorders.
You may also be interested in...
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.
Recent venture capital rounds funded the start-ups Airway, Alladapt, ALX Oncology, Azafaros, CANbridge, NeoTx, Spruce and Transcenta.
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.